A partnership has been signed between Sumitomo Dainippon Pharma and Angelini S.p.A.  to expand the availability in Europe of the atypical antipsychotic drug lurasidone hydrochloride (Latuda®). The European subsidiary of Sumitomo, Sunovion Pharmaceuticals Europe, has granted Angelini exclusive commercialization rights in 29 European countries plus Turkey.  Sumitomo Dainippon Pharma will also supply the bulk tablets or the final products to Angelini, that will begin to distribute the product in Italy by the end of 2017. Sunovion Europe will continue to distribute it in the United Kingdom, Switzerland, Norway, Finland, Sweden, Denmark and the Netherlands.